Updating the Management of the Dental Patient at Risk for Osteonecrosis of the Jaw Bone (ONJ) While Taking Bisphosphonates or Denosumab (Prolia®) - Latest Reports from the American Dental Association
Clinical Update From LexiComp
The American Dental Association (ADA) has released two reports which update previous reports on the management of the dental patient at risk for osteonecrosis of the jaw bone (ONJ) while taking bisphosphonates. The first is a 47-page report, dated December 2011 and posted on the ADA web site, entitled "Managing the Care of Patients Receiving Antiresorptive Therapy for Prevention and Treatment of Osteoporosis: Recommendations from the American Dental Association Council on Scientific Affairs." The second report was published as an executive summary on the same topic in the December 2011 issue of the Journal of the American Dental Association. Both reports update a 2008 report on the management and care of patients receiving oral bisphosphonate therapy, which was described in an earlier newsletter by this author. This month's newsletter describes and summarizes these latest reports.